[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ambulatory-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ambulatory-surgery":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644453","phase-4-remimazolam-flumazenil-versus-sevoflurane-for-hysteroscopic-day-surgery-100644453",false,"NCT07663877","Remimazolam-Flumazenil Versus Sevoflurane for Hysteroscopic Day Surgery","Remimazolam With Planned Flumazenil Reversal Versus Sevoflurane-based Balanced Anesthesia for Hysteroscopic Day Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Female patients aged 20 years or older.\n* Scheduled to undergo ambulatory hysteroscopic surgery under general anesthesia.\n* Able to provide written informed consent.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n\nExclusion Criteria:\n\n* Known hypersensitivity to benzodiazepines, remimazolam, or flumazenil.\n* Chronic use of benzodiazepines or opioids.\n* Severe hepatic dysfunction (Child-Pugh class B or C).\n* Severe renal dysfunction (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* Epilepsy or other significant neurologic disorders.\n* Pregnancy or breastfeeding.\n* Body mass index (BMI) ≥35 kg\u002Fm².\n* Severe obstructive sleep apnea.\n* Uncontrolled serious systemic disease that may preclude ambulatory surgery.\n* Refusal or inability to provide informed consent.","FEMALE","20 Years",{"count":19,"type":20},124,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This prospective, single-center, randomized controlled trial aims to compare remimazolam anesthesia with planned flumazenil reversal and sevoflurane-based balanced anesthesia in adult women undergoing ambulatory hysteroscopic surgery.\n\nParticipants will be randomly assigned in a 1:1 ratio to receive either remimazolam for induction and maintenance followed by flumazenil reversal or propofol induction followed by sevoflurane-based balanced anesthesia. The primary outcome is anesthesia-controlled time, defined as the sum of induction time and emergence time. Secondary outcomes include recovery profiles, postoperative symptoms, quality of recovery, hemodynamic stability, and the incidence of re-sedation. The study will evaluate whether a remimazolam-flumazenil strategy can improve operating room efficiency while maintaining recovery quality and safety comparable to conventional sevoflurane-based anesthesia in the ambulatory surgery setting.",[26,27,28],"Hysteroscopy","Ambulatory Surgery","General Anesthesia",[30,31,32,33,34,35,36,37,38],"remimazolam","flumazenil","sevoflurane","ambulatory surgery","day surgery","hysteroscopy","general anesthesia","recovery profile","anesthesia controlled time","NOT_YET_RECRUITING","2026-06-17",{"date":42,"type":43},"2026-06-23","ACTUAL",{"date":45,"type":20},"2026-06",{"date":47,"type":20},"2028-06",{"name":49,"class":50},"Chung-Ang University Gwangmyeong Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100638297","effectiveness-of-enhanced-recovery-after-surgery-eras-protocols-for-arthroscopic-anterior-cruciate-ligament-reconstruction-in-an-ambulatory-surgery-setting-100638297","NCT07602231","Effectiveness of Enhanced Recovery After Surgery (ERAS) Protocols for Arthroscopic Anterior Cruciate Ligament Reconstruction in an Ambulatory Surgery Setting","Evaluation of Clinical Outcomes and Feasibility of Enhanced Recovery After Surgery (ERAS) Protocols for Arthroscopic Anterior Cruciate Ligament Reconstruction in an Ambulatory Surgery Setting: A Non-randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of anterior cruciate ligament (ACL) rupture with indication for primary arthroscopic reconstruction\n* Voluntary agreement to participate in the study and signing of the informed consent form\n\nExclusion Criteria:\n\n* Patients with concomitant knee pathologies requiring additional surgical procedures in the same session\n* Presence of contraindications for ambulatory (day) surgery\n* Failure to adhere to the scheduled follow-up visits","ALL","18 Years",{"count":62,"type":20},115,[64],"NA","The anterior cruciate ligament (ACL) is a critical component for maintaining knee stability by resisting anterior tibial translation and internal rotation. ACL rupture is one of the most common orthopedic injuries, with an estimated incidence of 70 cases per 100,000 people annually. Since its inception, arthroscopic anterior cruciate ligament reconstruction (AACLR) has proven to be the gold standard, providing excellent outcomes in terms of graft longevity, return to sports, and patient satisfaction. Modern medical trends are shifting toward day-surgery protocols, where patients are discharged within 24 hours without an overnight stay. This model is identified as a major factor in enhancing the quality of postoperative recovery and patient satisfaction.\n\nThe Enhanced Recovery After Surgery (ERAS) program utilizes evidence-based multimodal interventions to reduce surgical stress and accelerate functional recovery. While day-surgery for AACLR has been proven feasible globally, its implementation in Vietnam remains limited due to systemic barriers. At the University Medical Center Ho Chi Minh City, although ERAS has been applied since 2022, the average length of stay for AACLR is 2.57 days, indicating significant room for optimization. This study aims to evaluate the current compliance with ERAS and the effectiveness of fully implementing these protocols to enable a day-surgery model.\n\nThe research is designed in two phases, including a descriptive cohort and a clinical intervention. The intervention focuses on 06 core ERAS measures:\n\n* Comprehensive preoperative counseling and education.\n* Reducing preoperative fasting by using Maltodextrin 2 hours before surgery.\n* Standardized anesthesia combined with local infiltration analgesia (LIA).\n* Multimodal analgesia to minimize opioid consumption.\n* Early drainage removal within 6-8 hours postoperatively.\n* Immediate postoperative rehabilitation starting in the recovery unit. Effectiveness will be measured through various outcomes: the quality of early recovery via the QoR-15 score, mechanical knee function via the Lysholm Knee Scoring Scale (LKSS), and health-related quality of life via the EQ-5D-5L. Furthermore, a cost-effectiveness analysis (CEA) will be conducted using the Incremental Cost-Effectiveness Ratio (ICER). The study expects to demonstrate that strict ERAS adherence makes day-surgery AACLR feasible, reduces hospital-acquired infections, optimizes operating room productivity, and lessens the financial burden on both patients and the healthcare system.",[67,68,27],"Anterior Cruciate Ligament Rupture","Enhanced Recovery After Surgery (ERAS) Protocol","2026-05-22",{"date":71,"type":43},"2026-05-28",{"date":73,"type":20},"2026-05-18",{"date":75,"type":20},"2027-06-30",{"name":77,"class":50},"University Medical Center Ho Chi Minh City (UMC)"]